BETHESDA, Md., Nov. 3, 2014 (GLOBE NEWSWIRE) -- AREVA Med announced today plans to build a new production facility in the United States. The company has acquired land in Plano, Texas, for the future site of a new facility for lead-212 production for use in medical applications. This site will also serve as the new offices and laboratory for AREVA Med's subsidiary Macrocyclics, Inc., the global leader of chelating agent technology.
This new facility will increase the company's production capabilities to meet the growing need of lead-212 for clinical developments of new cancer treatments in North America. It builds upon the existing lead-212 production capacities of the AREVA Med Maurice Tubiana Facility, located in Bessines-sur-Gartempe in the Limousin region of France, which has been in operation since 2013.
Patrick Bourdet, CEO of AREVA Med, said: "The construction of this new comprehensive facility in Plano will reinforce our presence and our proximity to our key partners in the United States. In addition to our production activities in France, we will be able to manufacture and distribute lead-212 locally to support the development of innovative, targeted, and powerful lead-212 treatments to combat cancer."
MORE ABOUT AREVA MED
AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high-purity lead-212 (²¹²Pb), a rare radioactive isotope that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and destroy certain very aggressive types of cancer cells. For more information: www.arevamed.com or www.targetedtrials.com.
CONTACT: Press Contact Alison Tise (301) 841-1673 Alison.Tise@areva.com @AREVAmed
Source: AREVA Med